logo

Aurinia Pharmaceuticals Inc. (AUPH)



Trade AUPH now with
  Date
  Headline
5/10/2022 6:15:34 AM Aurinia Pharma Q1 Net Loss $37.6 Mln Or $0.27/shr Vs. Net Loss $50.4 Mln Or $0.40/shr Last Year
2/28/2022 6:06:41 AM Aurinia Q4 Net Loss $33.3 Mln Or $0.25/Shr Vs Loss Of $8.1 Mln Or $0.06/Shr Last Year
12/29/2021 10:48:49 AM Aurinia Pharmaceuticals Down 3%
12/9/2021 6:27:05 AM Aurinia Announces Positive Topline Results From AURORA 2 Continuation Study Of LUPKYNIS For Active Lupus Nephritis
11/1/2021 10:26:05 AM Aurinia:reductions In Proteinuria Sustained With No Impact On Renal Function At 30 Months Of Treatment With Voclosporin
8/17/2021 6:09:10 AM Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune And Kidney-related Diseases
6/7/2021 7:24:47 AM Aurinia Announces Additional Analysis Of AURORA 1 Phase 3 Study Data Presented At ERA-EDTA 2021 Congress
4/8/2021 6:08:36 AM Aurinia Pharma Presents Addl Efficacy Data From AURA-LV And AURORA 1 Pivotal Trials Of LUPKYNIS In Lupus Nephritis
3/15/2021 6:15:45 AM Aurinia Announces Positive Cost-Effectiveness Assessment Of LUPKYNIS In Latest ICER Draft Evidence Report
2/22/2021 1:32:00 AM New Drugs Approved In January
2/8/2018 6:14:48 AM RBC Capital Markets Starts Aurinia Pharmaceuticals Inc. (AUPH) At Outperform With $9 Price Target